On his very active Twitter Martin Shkreli, chief executive officer of Turing Pharmaceuticals, told the Doctors Without Borders account that his company was investing in research and development – a claim the CEO has made repeatedly as part of his justification for the 5,000 percent increase of the 65-year-old toxoplasmosis drug, Daraprim.
Blood Pressure Drug Protects Against Symptoms of Multiple Sclerosis in Animal Models